biotech
biotech Articles
PhaseBio Pharmaceuticals shares jumped on Tuesday after the firm announced preliminary results from its mid-stage trial on subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.
Published:
Last Updated:
Baldness is something that many men fear as they age, and understandably so. But Aclaris Therapeutics may have found an answer to it in its most recent mid-stage clinical trial.
Published:
Last Updated:
Array BioPharma shares shot up on Monday after the firm announced that it would be acquired by Pfizer in an all cash transaction. The boards of directors of both companies have approved the merger...
Published:
Last Updated:
Savara shares were absolutely crushed on Thursday after the company released its late-stage results for its treatment of autoimmune pulmonary alveolar proteinosis. Unfortunately, the study did not...
Published:
Last Updated:
Whether you were in favor of or against the Affordable Care Act, it is likely of little surprise that the cost of health care has continued to rise. What also has risen handily is the number of...
Published:
Last Updated:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most...
Published:
Last Updated:
One relatively small clinical-stage biopharmaceutical player called Global Blood Therapeutics may be about to change how sickle cell disease treatment goes.
Published:
Last Updated:
Zynerba Pharma has just announced that the U.S. Patent and Trademark Office has issued a patent for the firm’s treatment of autism spectrum disorder with cannabidiol.
Published:
Last Updated:
CymaBay Therapeutics shares were nearly halved early Tuesday after the company provided an update from its midstage study of seladelpar for the treatment of nonalcoholic steatohepatitis.
Published:
Last Updated:
NovaBay shares absolutely exploded on Monday after the company announced that its eye care treatment would be readily available on Amazon.
Published:
Last Updated:
24/7 Wall St. has taken a look at Wedbush’s recent ASCO roundup, and we’ve picked out a few of the companies with the biggest upside potential going forward.
Published:
Last Updated:
InflaRx shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa.
Published:
Last Updated:
Amgen is the largest of all biotechs now, and it is being deemed an "ASCO winner" for cancer and oncology news. At least, that is the view of Credit Suisse.
Published:
Last Updated:
Here is why Genocea Biosciences is one of the big winners from the annual meeting of the American Society of Clinical Oncology (ASCO).
Published:
Last Updated:
Turning Point Therapeutics shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients.
Published:
Last Updated: